Scarica l'app Stockscreener
4.51
1.74%
-0.08
Dopo l'orario di chiusura:
4.49
-0.02
-0.44%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MXCT Giù?
Forum
Previsione
Precedente Chiudi:
$4.59
Aprire:
$4.59
Volume 24 ore:
410.62K
Relative Volume:
0.66
Capitalizzazione di mercato:
$475.73M
Reddito:
$45.44M
Utile/perdita netta:
$-35.43M
Rapporto P/E:
-13.26
EPS:
-0.34
Flusso di cassa netto:
$-25.39M
1 W Prestazione:
-3.22%
1M Prestazione:
+8.41%
6M Prestazione:
-6.04%
1 anno Prestazione:
-11.39%
Intervallo 1D:
$4.495
$4.74
Intervallo di 1 settimana:
$4.47
$4.90
Portata 52W:
$3.165
$5.26
Maxcyte Inc Stock (MXCT) Company Profile
Nome
Maxcyte Inc
Settore
Industria
Telefono
301-517-5556
Indirizzo
9713 KEY WEST AVENUE,, ROCKVILLE
Confronta MXCT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
4.51 | 475.73M | 45.44M | -35.43M | -25.39M | -0.34 |
|
ABT
Abbott Laboratories
|
127.93 | 221.89B | 41.95B | 13.40B | 6.49B | 7.65 |
|
BSX
Boston Scientific Corp
|
102.36 | 150.86B | 15.91B | 1.79B | 1.89B | 1.21 |
|
SYK
Stryker Corp
|
391.29 | 149.17B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
90.82 | 116.46B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
72.45 | 42.73B | 6.60B | 4.16B | 490.10M | 6.93 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-11-29 | Iniziato | Craig Hallum | Buy |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-08-24 | Iniziato | BTIG Research | Buy |
| 2021-08-24 | Iniziato | Cowen | Outperform |
| 2021-08-24 | Iniziato | Stephens | Overweight |
| 2021-08-24 | Iniziato | Stifel | Buy |
| 2021-08-24 | Iniziato | Wedbush | Outperform |
| 2021-08-24 | Iniziato | William Blair | Outperform |
Mostra tutto
Maxcyte Inc Borsa (MXCT) Ultime notizie
ConnectOne Bancorp (CNOB) Issues Press Release on Acquisition of SeQure Dx by MaxCyte - Defense World
MaxCyte, Inc. Acquires SeQure DX Inc. to Enhance Cell Engineering Offerings - Defense World
MaxCyte director exercises options, sells shares - Investing.com
MaxCyte Announces Executive Stock Transaction - TipRanks
MaxCyte, Inc. (NASDAQ:MXCT) Director John Joseph Johnston Sells 3,000 Shares - MarketBeat
MaxCyte Acquires SeQure Dx - FinSMEs
MaxCyte Buys SeQure Dx for Up to $7M - USA Herald
MaxCyte announces acquisition of SeQure Dx - ShareCast
Market news - Research the market
Glancy Prongay & Murray LLP Announces Investigation of MaxCyte, Inc. (MXCT) -January 30, 2025 at 10:37 am EST - Marketscreener.com
Sidley, Mintz Guide Gene Biz Acquisition Worth Up To $7M - Law360
MaxCyte buys gene therapy analytics firm SeQure Dx -January 30, 2025 at 08:56 am EST - Marketscreener.com
MaxCyte acquires SeQure Dx for $4.5M at closing, sees accretion - TipRanks
Cell Engineering Group MaxCyte Buys US-based SeQure Dx -January 30, 2025 at 05:05 am EST - Marketscreener.com
MaxCyte Acquires Gene Editing Analytics Company SeQure Dx -January 30, 2025 at 04:25 am EST - Marketscreener.com
MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments - The Manila Times
MaxCyte Expands Cell Engineering Capabilities with Acquisition of SeQure Dx - TipRanks
MaxCyte's Strategic Move: $7M Deal Transforms Gene Therapy Safety Testing Landscape - StockTitan
MaxCyte celebrates 25 years of innovation driving cell engineering-based therapeutics - MSN
BlackRock Increases Stake in MaxCyte, Inc. - TipRanks
Investors push MaxCyte (LON:MXCT) 9.7% lower this week, company's increasing losses might be to blame - Yahoo Finance
Should You Investigate MaxCyte, Inc. (LON:MXCT) At UK£3.65? - Simply Wall St
MaxCyte: Building the Future of Cell and Gene Therapy Innovation - MSN
JPMorgan Chase & Co. Decreases Stock Holdings in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte (NASDAQ:MXCT) Stock Price Down 5.8%Here's What Happened - MarketBeat
How to interpret MaxCyte Inc (MXCT)’s stock chart patterns - US Post News
Vertex Pharmaceutic (VRTX-Q) QuotePress Release - The Globe and Mail
MaxCyte Sees Increase in BlackRock Holdings - TipRanks
Recent Price Trend in MaxCyte (MXCT) is Your Friend, Here's Why - Yahoo Finance
BlackRock Increases Stake in MaxCyte to 7.57% - TipRanks
MaxCyte (NASDAQ: MXCT) Announces Preliminary Financial Results for Q4 and FY 2024ROCKVILLE, MD, January 13, 2025 — MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a prominent cell-engineering company specializing in platform technologies for adv - Defense World
MaxCyte Announces Change in Major Holdings by BlackRock - TipRanks
MaxCyte, Inc. (NASDAQ:MXCT) Stake Boosted by Barclays PLC - Defense World
Barclays PLC Has $645,000 Position in MaxCyte, Inc. (NASDAQ:MXCT) - MarketBeat
All You Need to Know About MaxCyte (MXCT) Rating Upgrade to Strong Buy - MSN
What Is MaxCyte, Inc.'s (LON:MXCT) Share Price Doing? - Yahoo Finance
Maxcyte general counsel sells shares worth $20,271 By Investing.com - Investing.com Nigeria
MaxCyte estimates higher Q4 core revenue from last year - MSN
David I. Sandoval Sells 4,466 Shares of MaxCyte, Inc. (NASDAQ:MXCT) Stock - MarketBeat
Maxcyte general counsel sells shares worth $20,271 - Investing.com
MaxCyte expects growth in core revenue for Q4 and full year 2024 - Investing.com Canada
MaxCyte (NASDAQ:MXCT) Shares Up 8.2%Here's Why - MarketBeat
MaxCyte expects growth in core revenue for Q4 and full year 2024 By Investing.com - Investing.com South Africa
MaxCyte flags full-year revenue at top end of expectations - ShareCast
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
MaxCyte Reports 2024 Financial Growth and Industry Milestones - TipRanks
Maxcyte Inc Azioni (MXCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):